New pill tested for severe transplant complication
NCT ID NCT04941404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug, TQ05105, in 13 people who had severe graft-versus-host disease (aGVHD) after a stem cell transplant and did not respond to steroids. The goal was to see if the drug is safe and can help control the disease. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLUCOCORTICOID-REFRACTORY AGVHD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hematology Hospital of the chinese Academy of Medical Sciences
Tianjing, Tianjing, 300020, China
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215008, China
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310012, China